Ukrainian biotechnology company Biopharma is turning education into a long-term part of its development strategy. The company invests about two million dollars a year in educational projects and plans to open new biology schools in Uzhhorod and Lviv this year.
Two such schools already operate in Kyiv and Bila Tserkva. Children attend free extracurricular classes in mathematics, chemistry and biology, working with strong teachers and laboratory-style tasks rather than standard tutoring formats.
From training to ecosystem building
Biopharma co-owner Kostiantyn Yefymenko frames the project as a way to grow a wider biotechnology environment, not simply as a pipeline for future company employees. His target is to help create 25 schools that can give motivated pupils early access to science and practical knowledge.
The logic is clear for a sector where qualified specialists are scarce and innovation depends on deep technical education. If more young people understand biology, chemistry and engineering at school age, Ukraine gains a stronger base for laboratories, medical production, startups and research teams.
For business, this is also a signal that investment in human capital can be part of industrial policy. Biopharma is known for plasma collection and medicines made from blood plasma, but the education initiative points to a broader ambition: to make biotechnology a field where Ukrainian talent can build companies, not only fill vacancies.
